





![Yale @ AWV-7785[57].jpg](https://images.squarespace-cdn.com/content/v1/66f1a668cb2280496659b3a0/f6e751ae-7da8-4189-8a99-08fc362f006f/Yale+%40+AWV-7785%5B57%5D.jpg)
Consortium Member of the Month
Our consortium member of the month for the month of September goes to Min Lu from Project 3 at Mount Sinai Health System!
Min Lu, MD, PhD
Min Lu is the employee of the month for the MPN-RC. This award is long overdue. Min is a pivotal investigator working with Dr. Ronald Hoffman in pursuing Project 3, which is trying to identify new drugs that can deplete or eliminate myelofibrosis stem cells. She uses in vitro assays as well as xenograft models to test the ability of these novel agents to deplete myelofibrosis stem cells. Min believes that by reducing the numbers of myelofibrosis stem cells, patients with myelofibrosis can live longer and have a better quality of life.
Min is a kind, patient, intelligent woman who is generous with her time. She has an excellent, subtle sense of humor. She always makes herself available to assist others in the Consortium. She is a fountain of knowledge about the cell biology of myelofibrosis stem cells. She is a native of China who has lived in NYC for over three decades. She has an adult daughter who lives in San Francisco. She is a superb photographer and enjoys travel.
The most remarkable feature of Min is her warmth and generosity that she displays daily. She is passionate about her work but understands that before there is success, there will be incremental steps forward and, at times, steps backward. She is in it for the long run. We all feel fortunate to have Min Lu as a colleague and a friend. She has been with Project 3 for almost 18 years, and working with her has been a treat for all who interact with her. Congratulations to Min Lu!!!
Nominated by: Dr. Ronald Hoffman
Min, thank you so much for all of the phenomenal work you have done for the consortium.
Keep up the great work!
Title: Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies
Author(s): Gita Thanarajasingam, Vishal Bhatnagar, Brie N. Noble,Ting-Yu Chen, Mallorie H. Fiero, Ron Hoffman, Molly Jeffery, Gina L. Mazza, John Mascarenhas, Ruben Mesa, Meena Murugappan, Joseph Ross, Surbhi Sidana, Rahma Warsame, Paul G. Kluet, and Amylou C. Dueck
MPN-RC Monthly Publication
MPN-RC Updates: ASH Conference 2024
-
Bridget Kelly Marcellino, MD,PhD
873 Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
-
Shivani Handa, MD
243 TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms